Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132540363> ?p ?o ?g. }
- W2132540363 endingPage "3341" @default.
- W2132540363 startingPage "3335" @default.
- W2132540363 abstract "Purpose New molecular targeted agents are needed for patients with non–small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral irreversible ErbB family blocker, has preclinical activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M. Patients and Methods This was a Japanese single-arm phase II trial conducted in patients with stage IIIB to IV pulmonary adenocarcinoma who progressed after ≥ 12 weeks of prior erlotinib and/or gefitinib. Patients received afatinib 50 mg per day. The primary end point was objective response rate (complete response or partial response) by independent review. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. Results Of 62 treated patients, 45 (72.6%) were EGFR mutation positive in their primary tumor according to local and/or central laboratory analyses. Fifty-one patients (82.3%) fulfilled the criteria of acquired resistance to erlotinib and/or gefitinib. Of 61 evaluable patients, five (8.2%; 95% CI, 2.7% to 18.1%) had a confirmed objective response rate (partial response). Median PFS was 4.4 months (95% CI, 2.8 to 4.6 months), and median OS was 19.0 months (95% CI, 14.9 months to not achieved). Two patients had acquired T790M mutations: L858R + T790M, and deletion in exon 19 + T790M; they had stable disease for 9 months and 1 month, respectively. The most common afatinib-related adverse events (AEs) were diarrhea (100%) and rash/acne (91.9%). Treatment-related AEs leading to afatinib discontinuation were experienced by 18 patients (29%), of whom four also had progressive disease. Conclusion Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both." @default.
- W2132540363 created "2016-06-24" @default.
- W2132540363 creator A5004282323 @default.
- W2132540363 creator A5017095102 @default.
- W2132540363 creator A5022022857 @default.
- W2132540363 creator A5025565389 @default.
- W2132540363 creator A5032337115 @default.
- W2132540363 creator A5037461196 @default.
- W2132540363 creator A5037746646 @default.
- W2132540363 creator A5038687249 @default.
- W2132540363 creator A5039221262 @default.
- W2132540363 creator A5044605303 @default.
- W2132540363 creator A5047900853 @default.
- W2132540363 creator A5065809272 @default.
- W2132540363 creator A5066357817 @default.
- W2132540363 creator A5066700160 @default.
- W2132540363 creator A5086229141 @default.
- W2132540363 date "2013-09-20" @default.
- W2132540363 modified "2023-10-10" @default.
- W2132540363 title "LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both" @default.
- W2132540363 cites W1819148429 @default.
- W2132540363 cites W1964479812 @default.
- W2132540363 cites W1979332174 @default.
- W2132540363 cites W2019236425 @default.
- W2132540363 cites W2063391304 @default.
- W2132540363 cites W2068691832 @default.
- W2132540363 cites W2074871758 @default.
- W2132540363 cites W2079251910 @default.
- W2132540363 cites W2090029719 @default.
- W2132540363 cites W2096786080 @default.
- W2132540363 cites W2109080255 @default.
- W2132540363 cites W2111662961 @default.
- W2132540363 cites W2112602910 @default.
- W2132540363 cites W2114095518 @default.
- W2132540363 cites W2129360604 @default.
- W2132540363 cites W2132157071 @default.
- W2132540363 cites W2133741785 @default.
- W2132540363 cites W2138851777 @default.
- W2132540363 cites W2139248078 @default.
- W2132540363 cites W2142865455 @default.
- W2132540363 cites W2143859186 @default.
- W2132540363 cites W2152905269 @default.
- W2132540363 cites W2160336497 @default.
- W2132540363 cites W2160982674 @default.
- W2132540363 cites W2166084034 @default.
- W2132540363 cites W2332183914 @default.
- W2132540363 doi "https://doi.org/10.1200/jco.2012.45.0981" @default.
- W2132540363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23816963" @default.
- W2132540363 hasPublicationYear "2013" @default.
- W2132540363 type Work @default.
- W2132540363 sameAs 2132540363 @default.
- W2132540363 citedByCount "289" @default.
- W2132540363 countsByYear W21325403632013 @default.
- W2132540363 countsByYear W21325403632014 @default.
- W2132540363 countsByYear W21325403632015 @default.
- W2132540363 countsByYear W21325403632016 @default.
- W2132540363 countsByYear W21325403632017 @default.
- W2132540363 countsByYear W21325403632018 @default.
- W2132540363 countsByYear W21325403632019 @default.
- W2132540363 countsByYear W21325403632020 @default.
- W2132540363 countsByYear W21325403632021 @default.
- W2132540363 countsByYear W21325403632022 @default.
- W2132540363 countsByYear W21325403632023 @default.
- W2132540363 crossrefType "journal-article" @default.
- W2132540363 hasAuthorship W2132540363A5004282323 @default.
- W2132540363 hasAuthorship W2132540363A5017095102 @default.
- W2132540363 hasAuthorship W2132540363A5022022857 @default.
- W2132540363 hasAuthorship W2132540363A5025565389 @default.
- W2132540363 hasAuthorship W2132540363A5032337115 @default.
- W2132540363 hasAuthorship W2132540363A5037461196 @default.
- W2132540363 hasAuthorship W2132540363A5037746646 @default.
- W2132540363 hasAuthorship W2132540363A5038687249 @default.
- W2132540363 hasAuthorship W2132540363A5039221262 @default.
- W2132540363 hasAuthorship W2132540363A5044605303 @default.
- W2132540363 hasAuthorship W2132540363A5047900853 @default.
- W2132540363 hasAuthorship W2132540363A5065809272 @default.
- W2132540363 hasAuthorship W2132540363A5066357817 @default.
- W2132540363 hasAuthorship W2132540363A5066700160 @default.
- W2132540363 hasAuthorship W2132540363A5086229141 @default.
- W2132540363 hasBestOaLocation W21325403631 @default.
- W2132540363 hasConcept C121608353 @default.
- W2132540363 hasConcept C126322002 @default.
- W2132540363 hasConcept C143998085 @default.
- W2132540363 hasConcept C203092338 @default.
- W2132540363 hasConcept C2776256026 @default.
- W2132540363 hasConcept C2776694085 @default.
- W2132540363 hasConcept C2777930144 @default.
- W2132540363 hasConcept C2778087573 @default.
- W2132540363 hasConcept C2778570526 @default.
- W2132540363 hasConcept C2778822529 @default.
- W2132540363 hasConcept C2779438470 @default.
- W2132540363 hasConcept C2780580887 @default.
- W2132540363 hasConcept C2780586478 @default.
- W2132540363 hasConcept C2909325608 @default.
- W2132540363 hasConcept C31760486 @default.
- W2132540363 hasConcept C535046627 @default.
- W2132540363 hasConcept C71924100 @default.
- W2132540363 hasConcept C90924648 @default.